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OBJECTIVE—Rapamycin is an immunosuppressive drug cur-
rently used to prevent graft rejection in humans, which is
considered permissive for tolerance induction. Rapamycin al-
lows expansion of both murine and human naturally occurring
CD4
CD25
FOXP3
 T regulatory cells (nTregs), which are
pivotal for the induction and maintenance of peripheral toler-
ance. Preclinical murine models have shown that rapamycin
enhances nTreg proliferation and regulatory function also in
vivo. Objective of this study was to assess whether rapamycin
has in vivo effects on human nTregs.
RESEARCH DESIGN AND METHODS—nTreg numbers and
function were examined in a unique set of patients with type 1
diabetes who underwent rapamycin monotherapy before islet
transplantation.
RESULTS—We found that rapamycin monotherapy did not alter
the frequency and functional features, namely proliferation and
cytokine production, of circulating nTregs. However, nTregs
isolated from type 1 diabetic patients under rapamycin treatment
had an increased capability to suppress proliferation of CD4

CD25
 effector T-cells compared with that before treatment.
CONCLUSIONS—These ﬁndings demonstrate that rapamycin
directly affects human nTreg function in vivo, which consists of
reﬁtting their suppressive activity, whereas it does not directly
change effector T-cell function. Diabetes 57:2341–2347, 2008
T
ype 1 diabetes results from a chronic destruction
of insulin-producing pancreatic -cells mediated
by autoreactive T-cells (1). Circulating T-cells
able to react against -cell autoantigens have
been demonstrated in both healthy donors and type 1
diabetic subjects (2). However, we recently showed that
naı ¨ve T-cells recognizing -cell autoantigens are present in
each individual, irrespective of disease occurrence, whereas
diabetes-speciﬁc autoreactive T-cells that have undergone
sustained in vivo proliferation and differentiation into
memory T-cells are a hallmark of patients only (3). These
data suggest that active mechanisms of peripheral toler-
ance present in healthy individuals are likely to be inade-
quate in type 1 diabetic subjects.
Among the several mechanisms accounting for periph-
eral tolerance, suppression mediated by regulatory T-cells
(Tregs) is considered crucial for controlling autoimmune
responses (rev. in 4). Various subsets of Tregs have been
described so far, and the naturally occurring CD4
 Tregs
(nTregs) represent the only cell population originating
from the thymus and therefore present since birth in the
circulation, where they represent 5–10% of total CD4

T-cells. nTregs are crucial for maintaining tolerance by
downregulating undesired immune responses to self- and
non–self-antigens. nTregs are deﬁned on the basis of
constitutive high expression of the interleukin (IL)-2R
(CD25), the transcription factor forkhead box P3 (FOXP3)
(5), low or absent expression of the IL-7R (CD127) (6,7),
and the inability to produce IL-2 and to proliferate in
vitro (5).
The variety of human autoimmune diseases in which a
defect in nTreg function has been proposed is of interest,
raising the possibility that this may be a common mecha-
nism leading to uncontrolled immune responses to self-
antigens (8). It remains controversial whether nTregs are
defective in type 1 diabetic patients. Some reports suggest
that normal numbers of circulating nTregs are present in
type 1 diabetic patients, but their suppressive activity is
defective in vitro (9–11). However, others do not show an
in vitro suppressive defect in type 1 diabetes nTregs
compared with those in healthy individuals (12). Studies in
mice clearly demonstrate that depletion of nTregs results
in systemic autoimmune diseases (diabetes included), and
adoptive transfer of nTregs prevents development of type
1 diabetes in NOD mice and, in some experimental set-
tings, also cures ongoing disease (13–15). As a result of
these preclinical studies, nTregs are nowadays considered
a promising therapeutic tool for reestablishing self-toler-
ance in type 1 diabetes and other T-cell–mediated diseases
(16). As a therapeutic approach, one can envisage either to
adoptively transfer nTregs previously expanded ex vivo
(because of their limited circulating number) or to directly
expand nTregs and/or boost their suppressive function in
vivo with selected immunomodulatory compounds.
We demonstrated that rapamycin, a non-calcineurin
inhibitor currently used to prevent acute graft rejection
after allogeneic transplants (17), allows expansion of
murine nTregs in vitro (18). In addition, in vivo adminis-
tration of rapamycin prevents type 1 diabetes in NOD mice
and reestablishes long-term tolerance to self-antigens
through the expansion of nTregs (19). In humans, rapamy-
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DIABETES, VOL. 57, SEPTEMBER 2008 2341cin promotes nTreg expansion in vitro through selective
inhibition of effector T-cell proliferation (20) and does not
interfere with de novo induction of Treg cells from naı ¨ve
CD4
 T-cells (21). Both of these biological effects can
favor tolerance induction in vivo. It has been recently
shown that in renal transplant recipients who underwent
profound T-cell depletion by Campath-1H induction, main-
tenance therapy with rapamycin but not cyclosporine A
increases the pool of circulating CD4
CD25
highFOXP3

T-cells (22). Because rapamycin is commonly adminis-
tered in transplanted patients in combination with other
drugs, so far it has not been feasible to deﬁne whether
rapamycin has a direct effect in vivo on human nTregs as
we previously demonstrated in vitro (20) and in a preclin-
ical murine model of type 1 diabetes (19).
We have been using a clinical protocol in which rapa-
mycin monotherapy is given to long-term type 1 diabetic
patients before islet transplantation to reach therapeutic
plasma levels at the time of islet infusion (23), followed by
maintenance immunotherapy as described by the Edmon-
ton group (24). This study provided the opportunity to
investigate the in vivo effect of rapamycin therapy on
nTreg number and function in patients with autoim-
mune disease. We demonstrate that rapamycin treat-
ment does not modify number, phenotype, ability to
proliferate, and ability to produce cytokines of circulat-
ing CD4
CD25
brightFOXP3
 nTregs. However, the sup-
pressive capacity of highly puriﬁed CD4
CD25
bright T-cells
is improved in type 1 diabetic patients during rapamycin
treatment compared with that of the same patients tested
before treatment. Thus, rapamycin has an in vivo direct
effect on human nTreg function, supporting its use in
clinical immunosuppressive regimens aimed at tolerance
induction.
RESEARCH DESIGN AND METHODS
Patients and blood collection. Patients with long-lasting type 1 diabetes
(5 years) who had reduced awareness of hypoglycemia, brittle diabetes, or
progressive complications, despite optimization of insulin therapy, were
candidates for solitary islet transplant at the Telethon-Juvenile Diabetes
Research Foundation Center for Beta Cell Replacement, San Raffaele Scien-
tiﬁc Institute, Milan. In this study, six patients received rapamycin treatment
at 0.1 mg  kg
1  day
1 (Table 1). Each patient is identiﬁable by a speciﬁc
symbol, which can be followed throughout the manuscript (e.g., patient
Hsr-066-ITA-rp06 is recognizable by the E symbol). Peripheral blood was
obtained before and during rapamycin treatment (before receiving islet
transplantation) after informed consent and ethics committee approval. Five
normal donors of similar age and sex to the patients were recruited through
the courtesy of Centro Trasfusionale, San Raffaele Scientiﬁc Institute, Milan,
and donated peripheral blood after informed consent and ethics committee
approval.
Peripheral blood mononuclear cell isolation. Peripheral blood mononu-
clear cells (PBMCs) were isolated over a Ficoll-Hypaque (Amersham Pharma-
cia Biotech Europe, Uppsala, Sweden) density gradient centrifugation from
sodium-heparinized venous blood samples and washed twice in PBS (Cam-
brex-Biowhittake, Walkersville, MD). All samples were frozen in FCS (Cam-
brex-Biowhittaker) containing 10% dimethyl sulfoxide (Sigma-Aldrich, St.
Louis, MO) in a controlled-rate automated freezing device to 80°C and then
stored in liquid nitrogen. All of the experiments were performed on thawed
cells. Samples from the same type 1 diabetic patient collected before and
during rapamycin treatment were tested simultaneously in parallel to cells
from one normal donor. Each patient was tested alongside a separate normal
donor.
Flow cytometry. Thawed PBMCs were stained for surface antigens with the
following monoclonal antibodies (mAbs) all purchased from BD Pharmingen
(San Diego, CA): anti-CD4 PerCP (peridinin chlorophyll protein) (clone SK3),
anti-CD25 allophycocyanin (clone 2A3), anti-CD62L phycoerytrin (PE) (clone
SK11), anti-CD127 PE (clone M21), anti-CTLA4 biotin (clone BN13), anti-
CD45RO ﬂuorescein isothiocyanate (FITC) (clone UCHL1), and anti–HLA-DR
PE (clone TU36) mAbs. Intracellular staining for human FOXP3 was per-
formed using the anti FOXP3-Alexa 488 mAb (clone 259D; BioLegend, San
Diego, CA) according to the manufacturer’s instructions. At least 20,000
events were acquired from each sample on a BD FACScalibur and analyzed
with FCS Express V3 software.
Cell sorting. Thawed PBMCs were stained with anti-CD4 FITC (clone SK3;
BD Pharmingen) and anti-CD25 PE (clone 2A3; BD Pharmingen). CD4

CD25
bright (top 1–2%) and CD4
CD25
 fractions were sorted with a ﬂuores-
cence-activated cell sorter (FACS; BD FACSvantage) (for gating strategy, see
Fig. 2). Sorted CD4
CD25
 and CD4
CD25
bright T-cells had a purity of 96–98%
both from type 1 diabetic patients (before and during rapamycin treatment)
and from normal donors. Sorting CD4
CD127
lowCD25
bright T-cells provided a
population of nTregs with suppressive ability similar to those sorted as
CD4
CD25
bright cells, contrary to what has previously been published (Fig. 1)
TABLE 1
T1D patient description
Patient code
Patient
symbol*
Age
(years) Sex
Diabetes
duration
(years)
RAPA
treatment
(days)
RAPA†
(ng/ml)
C-peptide
(ng/ml) A1C (%)
EIR (units 
kg
1  day
1)
PRE RAPA PRE RAPA PRE RAPA
Hsr-066-ITA-rp06  39 M 32 109 9 0.70 0.77 9.5 8.9 0.63 0.53
Hsr-065-ITA-rp05  40 F 11 153 24 0.15 0.28 8.7 8.7 0.89 0.79
Hsr-069-ITA7-rp07 „ 31 M 26 32 21 0.02 0.02 9.1 nt 0.63 0.51
Hsr-063-ITA-rp03 Œ 48 F 37 130 5 0.03 0.16 6.2 6.6 0.73 0.71
Hsr-064-ITA-rp04  33 F 21 109 12 0.02 0.02 8.9 9.5 0.65 0.57
Hsr-ATG-ITA-rp02 f 32 M 7 97 5 0.01 0.01 8.7 8.7 0.74 0.42
Mean 39.2 22.3 105 13
Range 31–48 7–37 32–153 5–24
*Symbols recalled throughout the manuscript. †Circulating plasma rapamycin concentration. EIR, exogenous insulin requirements; PRE,
sample before rapamycin treatment; RAPA, sample during rapamycin treatment.
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FIG. 1. In vitro suppressive function of FACS-sorted CD4
CD25
bright
CD127
 and CD4
CD25
bright T-cells. FACS-sorted 10
4 effector CD4

CD25
 T-cells (Eff.) were activated polyclonally with magnetic beads
coated with anti-CD3CD28 mAbs alone or in the presence of equal
amounts of FACS-sorted autologous CD4
CD25
brightCD127
 nTregs
(left)o rC D 4
CD25
bright nTregs (right). Cell proliferation was as-
sessed in all cultures at day 4 after addition of [
3H]thymidine for the
last 18 h of culture. Percentage of suppression is indicated. One
representative experiment of four is shown.
AFFECT OF RAPAMYCIN ON HUMAN nTreg FUNCTION
2342 DIABETES, VOL. 57, SEPTEMBER 2008(6). We therefore concluded that there was no need to sort nTregs based on
the expression of CD127.
Suppression assay. FACS-sorted CD4
CD25
 T-cells were plated at 1 	 10
4
cells per well (in 200 
l X-vivo 15 [Cambrex-Biowhittaker] supplemented with
10% human serum AB [Sigma], 100 units/ml penicillin, and 100 units/ml
streptomycin) in 96 round-bottom plates and stimulated with anti CD3/CD28-
coupled beads (one bead per six cells) (Invitrogen-Dynal, Oslo, Norway).
FACS-sorted CD4
CD25
bright T-cells were added at a 1:1 ratio (CD4
CD25
:
CD4
CD25
bright). T-cell proliferation was assessed at day 4, after addition of
[
3H]thymidine for the last 18 h of culture (1 
Ci per well) (Amersham,
Buckingham, U.K.). Suppressive activity of CD4
CD25
bright T-cells was mea-
sured as inhibition of cell proliferation of CD4
CD25
 T-cells compared with
proliferation of CD4
CD25
 T-cells stimulated in the absence of nTregs.
Historical data from our laboratory demonstrate that repeated measures of
suppression using normal donor cells is relatively consistent (data not
shown). In one patient, the suppression assay was performed using the CFSE
dilution assay. Brieﬂy, 1 	 10
5 FACS-sorted CD4
CD25
 T-cells were stained
with CFSE (Molecular Probes, Eugene, OR) as described previously (18).
Following the same protocol as for CFSE staining, 1 	 10
5 FACS-sorted
CD4
CD25
high T-cells were ﬁrst stained with SNARF (Molecular Probes) and
were subsequently mixed with an equal number of CFSE
CD4
CD25
 T-cells
in round-bottom 96-well plates precoated with 10 
g/ml anti-CD3 and 1 
g/ml
soluble anti-CD28 mAbs (BD Biosciences). Seven days later, the cells were
collected and analyzed by FACS. The proportion of CFSE
 (FL-1) T-cells
proliferating in vitro was calculated by gating on lymphocytes plus alive
cells (TOPRO
 FL-4) (Molecular Probes) and by excluding SNARF
 (FL-2)
cells. The number of gated cells (events) in a given cycle (division: n) was
divided by 2 raised to power n, to calculate the percentage of original
precursor cells from which they arose. The sum of original precursors from
division 1–6 represents the number of precursors cells that proliferated. The
percentage of CFSE
 divided cells was calculated by ([no. of precursors that
proliferated1–6/no. of total precursors0–6] 	 100) (18). The percentage of
CD4
 T-cells CFSE
 cells divided in the presence of CD4
CD25
high T-cells
was compared with the percentage of CD4
 CFSE
 divided T-cells in the
absence of nTregs.
Cytokine detections. FACS-sorted CD4
CD25
 and CD4
CD25
bright T-cells
were plated at 1 	 10
4 cells per well (in 200 
l X-vivo 15 supplemented with
10% human serum AB, 100 units/ml penicillin, and 100 units/ml streptomycin)
in 96 round-bottom plates and stimulated with anti CD3/CD28-coupled beads
(one bead per six cells) (Invitrogen-Dynal). Culture supernatant was collected
3 days after activation and frozen at 80°C. Detection of IL-2, interferon-
(IFN-), tumor necrosis factor- (TNF-), IL-4, IL-5, and IL-10 was performed
using a cytometric bead array kit (BD Pharmingen) according to the manu-
facturer’s instructions.
Statistical analysis. Comparisons between patients and normal donors were
performed using Student’s t test. Comparisons between samples collected
before and samples collected during rapamycin treatment were performed
using Student’s paired t test. In all cases, two-tailed P  0.05 was considered
signiﬁcant. Analyses were performed using the Prism V4.03 software (Graph-
Pad, San Diego, CA).
RESULTS
To deﬁne whether rapamycin monotherapy modiﬁes num-
ber and phenotype of circulating nTregs, PBMCs isolated
from type 1 diabetic patients before and during rapamycin
treatment were thawed and tested for the expression of
regulatory-cell markers (6,25,26). The percentage of circu-
lating CD4
 T-cells was not altered by rapamycin treat-
ment (Fig. 2A). Similarly, the percentage of CD25
bright
T-cells, within the CD4
 T-cell subset, did not change
during rapamycin monotherapy compared with that before
treatment (Fig. 2B). Markers of regulatory T-cells (namely,
FOXP3, CD127, CTLA-4, HLA-DR, CD45RO, and CD62L)
were also similarly expressed by CD4
CD25
bright T-cells
isolated before and during rapamycin monotherapy
(Fig. 2C).
To determine whether rapamycin therapy modiﬁes the
functional features of peripheral CD4
CD25
 effector
T-cells and CD4
CD25
bright T-cells (which should be en-
riched for nTregs), their proliferative capacity, cytokine
production proﬁle, and suppressive function were tested
in vitro. The two T-cell subsets were ﬁrst puriﬁed from
type 1 diabetic patients before and during rapamycin
monotherapy and from age-matched normal donors by
ﬂow cytometry (Fig. 3A). Puriﬁed CD4
CD25
bright T-cells
were all FOXP3
 (data not shown). FACS-sorted T-cells
were activated in vitro by T-cell receptor–mediated poly-
clonal stimulation. Type 1 diabetic CD4
CD25
 effector
T-cells proliferated to a similar extent to those isolated
from normal donors, irrespective of rapamycin therapy
(Fig. 3B). CD4
CD25
bright T-cells from type 1 diabetic
subjects were anergic both before and during rapamycin
treatment, as were those isolated from normal donors
(Fig. 3B), and their proliferative capacity was restored
on addition of exogenous IL-2 (data not shown). These
data show that rapamycin does not alter the prolifera-
tive capacity of effector T-cells isolated from type 1
diabetic patients. In addition, the anergic phenotype of
CD4
CD25
bright T-cells (i.e., [H
3]thymidine incorpora-
tion 1,000 cpm upon activation) puriﬁed from both
type 1 diabetic patients (before and during rapamycin
treatment) and normal donors suggests that the sorted
T-cells comprise mainly nTregs that are not contami-
nated with activated CD4
CD25
 effector T-cells with
high proliferative capacity.
To ascertain whether rapamycin monotherapy alters the
cytokine production proﬁle of CD4
CD25
 effector T-cells
and CD4
CD25
bright nTregs, the sorted CD4
 T-cell sub-
sets were activated polyclonally, and supernatants were
collected for cytokine measurements. The ability of type 1
diabetes CD4
CD25
 effector T-cells to produce both Th1
(i.e., IL-2, IFN-, and TNF-) and Th2 (i.e., IL-4, IL-5, and
IL-10) cytokines was similar before and during rapamycin
monotherapy, and the cytokine levels were comparable
with those of CD4
CD25
 T-cells isolated from normal
donors (Fig. 4). Sorted CD4
CD25
bright T-cells, due to their
anergic state, did not produce signiﬁcant levels of any of
the tested cytokines, irrespective of rapamycin treatment
(data not shown). Overall, effector CD4
CD25
 T-cells
isolated from type 1 diabetic patients are functionally
similar before and during rapamycin monotherapy, in
terms of proliferative ability and cytokine production
proﬁle, and are not different from those isolated from
normal donors. The same holds true for CD4
CD25
bright
nTregs.
Finally, the ability of sorted CD4
CD25
bright nTregs to
suppress proliferation of CD4
CD25
 effector T-cells was
tested in vitro. CD4
CD25
bright nTregs isolated from type 1
diabetic subjects during rapamycin monotherapy sup-
pressed syngeneic effector T-cells signiﬁcantly more than
those isolated before treatment (Fig. 5A, compare pre-
treatment samples and samples during rapamycin treat-
ment). The average level of nTreg suppression in type 1
diabetic patients before rapamycin therapy was signiﬁ-
cantly reduced in comparison with that of normal donors
(Fig. 5A, compare pretreatment samples and normal do-
nors). On the contrary, type 1 diabetes nTregs isolated
during rapamycin therapy suppressed to the same levels of
normal donor nTregs (Fig. 5A, compare patients during
rapamycin treatment and normal donors). Type 1 diabetes
nTregs isolated during rapamycin treatment had an in-
creased suppressive capacity compared with those iso-
lated before treatment also when normal donor CD4

CD25
 effector T-cells were used as responder cells (Fig.
5B). These data indicate that the increased suppressive
ability observed during rapamycin monotherapy is due to
an improved capacity of type 1 diabetes nTregs to sup-
press proliferation of CD4
CD25
 effector T-cells rather
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FIG. 2. Percentages and phenotype of circulating CD4
 T-cells in type 1 diabetic patients before and during rapamycin treatment. PBMCs isolated
from type 1 diabetic patients before (PRE) and during (RAPA) rapamycin treatment were stained with the indicated mAbs and analyzed by FACS.
Representative plots of samples collected and analyzed from patient Hsr-064-ITA-rp04, before and during rapamycin therapy, are shown on the
left. Numbers indicate how many cells express each marker. Graphs including analyses performed in all patients (each distinguishable by a
speciﬁc symbol, see Table 1) are shown on the right, and the solid line represents the average level of type 1 diabetes PRE and type 1 diabetes
RAPA samples. Statistical analysis is shown in each graph. A: Percentages of total CD4
 T-cells within PBMCs. B: Percentages of CD25
bright T-cells
within the CD4
 T-cell compartment. C: Percentages of CD127
FOXP3
, CTLA-4
, CD45RO
, HLA-DR
, and CD62L
 cells within the
CD4
CD25
bright T-cells. FOXP3 mean ﬂuorescence intensity of CD4
CD25
bright CD127
 FOXP3
 cells is shown for both PRE and RAPA samples.
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CD4
CD25
 effector T-cells to be suppressed in vitro on in
vivo exposure to rapamycin. The observation that CD4

CD25
bright nTregs isolated from normal donors suppressed
type 1 diabetes CD4
CD25
 effector T-cells isolated be-
fore and during rapamycin treatment to a similar extent
(Fig. 5C) further supports the hypothesis that rapamycin
monotherapy directly improves nTregs suppressive activ-
ity rather than modifying the susceptibility of effector
T-cells to be suppressed.
DISCUSSION
We have shown that rapamycin monotherapy in long-term
type 1 diabetic patients does not alter the frequency and
total number of circulating CD4
CD25
brightFOXP3

CD127
low/neg nTregs. Similarly, the ability of rapamycin-
exposed nTregs to proliferate and produce cytokines in
vitro is unaffected by the therapy. Interestingly, peripheral
nTregs isolated from type 1 diabetic patients during rapa-
mycin treatment have an intrinsic improved capacity to
suppress proliferation of syngeneic and allogeneic CD4

CD25
 effector T-cells, compared with that before treat-
ment. Rapamycin therapy, therefore, reﬁts nTreg
suppressive activity, but it does not directly change effec-
tor T-cells.
Rapamycin administration to pre-diabetic NOD mice
leads to expansion of nTregs that accumulate in the
pancreatic lymph nodes and block diabetes development
(19). Similarly, C57BL/6 mice receiving rapamycin for 14
days show an enhanced ratio between nTregs and CD4

T-cells in the spleen and thymus (27). In humans, the
frequency of circulating nTregs in renal transplant recipi-
ents is preserved under rapamycin treatment, whereas it is
signiﬁcantly decreased during therapy with calcineurin
inhibitors (28). Similarly, we observed that rapamycin
monotherapy preserves the number of circulating nTregs.
In humans, a large expansion of peripheral nTregs has
been observed only in renal transplant recipients receiving
rapamycin as maintenance immunosuppressive therapy
after profound T-cell depletion with Campath-1H (22). The
absence of such expansion in patients receiving the cal-
cineurin inhibitor cyclosporine A (22) suggests that acute
lymphopenia and calcineurin-mediated signaling are im-
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FIG. 3. Proliferative capacity of FACS-sorted CD4
CD25
 and
CD4
CD25
bright T-cells. A: PBMCs from type 1 diabetes before and
during rapamycin treatment and from normal donors were FACS
sorted upon staining with anti-CD4 and -CD25 mAbs. One representa-
tive gating strategy and purity of CD4
CD25
 and CD4
CD25
bright
T-cells isolated from patient Hsr-066-ITA-rp06 before rapamycin ther-
apy are shown. B: The two sorted T-cell subsets (CD4
CD25
 T-cells
on the left and CD4
CD25
bright T-cells on the right) were activated
polyclonally with beads coated with anti-CD3CD28 mAbs, and cell
proliferation was assessed at day 4 after addition of [
3H]thymidine for
the last 18 h of culture. Each patient is identiﬁable by a speciﬁc symbol,
and each star represents a different normal donor. The solid line
represents the average levels of T-cell proliferation of samples from
type 1 diabetic patients pretreatment (PRE), type 1 diabetic patients
during treatment (RAPA), and normal donors (ND). The cells were
considered anergic when T-cell proliferation was <1,000 counts per
minute (cpm).
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FIG. 4. Cytokine production proﬁle of FACS-sorted CD4
CD25
 T-
cells. FACS-sorted CD4
CD25
 T-cells isolated from PBMCs of type 1
diabetic patients before (PRE) and during (RAPA) rapamycin treat-
ment and from normal donors (ND) were activated polyclonally (5 
10
4 cells/ml) with beads coated with anti-CD3
CD28 mAbs, and super-
natants were collected 72 h after activation. The indicated cytokines
were evaluated by cytokine-bead array. Each patient is identiﬁable by
a speciﬁc symbol, and each star represents a different normal donor.
The solid line represents average levels of cytokines produced by type
1 diabetes PRE, type 1 diabetes RAPA, and ND CD4
CD25
 T-cells.
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humans.
Rapamycin treatment causes G1 arrest in a variety of
cell types, including T-cells (29). However, we demon-
strated that, in contrast to CD4
CD25
 effector T-cells,
human nTregs are resistant to the antiproliferative effect
of rapamycin in vitro (20). This antiproliferative effect is
operational as long as rapamycin is present in the culture,
because restimulation of rapamycin-exposed CD4
CD25

effector T-cells in the absence of rapamcyin leads to
normal T-cell proliferation (Fig. 2B; 20).
The existence of CD4
CD25
 nTregs with defective
suppressor function in type 1 diabetic patients has been
demonstrated in some studies (9–11), whereas others
showed that type 1 diabetes CD4
CD25
 Tregs are as
suppressive as those of normal donors (12). Among the
factors that could account for the discrepancies in these
studies is the different purity of the tested Tregs. Studies
have used FACS-sorted CD4
CD25
bright T-cells (12) or
bead-puriﬁed CD4
CD25
 T-cells (9–11), and it is possible
that a defect in CD4
CD25
 nTregs was due to confound-
ing effects from contaminating T effector cells when
bead-puriﬁed T-cells were used. To reduce this risk, we
FACS-sorted both CD4
CD25
bright T-cells (falling in the
top 1–2% of CD25
 cells) and CD4
CD25
 effector T-cells
from type 1 diabetic patients and normal donors. Func-
tional data, in terms of cell proliferation and cytokine
production proﬁle of both CD4
CD25
 and CD4

CD25
bright T-cells, prove that in the current study, we are
comparing similar T-cell subsets isolated from type 1
diabetic subjects before and during rapamycin treatment
and from normal donors. Using these highly puriﬁed
T-cells, we show that the suppressive function of nTregs
freshly isolated from type 1 diabetic patients before rapa-
mycin therapy is signiﬁcantly reduced compared with that
of normal donors. Although the number of patients was
low, some patients had nTregs that were completely
absent in suppressive function as determined by current
protocols. Moreover, quantitative suppression by nTregs
isolated from normal donors was relatively similar be-
tween subjects, whereas it varied markedly between type
1 diabetic patients. Thus, type 1 diabetic subjects appear
to be variable in their freshly isolated peripheral nTreg
function.
Increased and restored suppressive function of nTregs
was observed in type 1 diabetic patients undergoing
rapamycin monotherapy. These results are in accordance
to our in vitro data, which demonstrated that peripheral
CD4
 T-cells isolated from type 1 diabetic subjects and
expanded in vitro with rapamycin have the same suppres-
sive ability as those isolated from normal donors (20). The
improved nTreg activity during rapamycin therapy is un-
likely due to differences in numbers of bona ﬁde nTregs
(i.e., FOXP3
CD127
low/neg) in the type 1 diabetic CD4

CD25
bright T-cells isolated during rapamycin treatment
compared with that before treatment because they are
equally present, irrespective of rapamycin therapy. FOXP3
can be upregulated in T-cells on activation, and this might
inﬂuence their suppressive function (30,31). We tested
whether nTregs isolated during rapamycin treatment differ
in their ability to upregulate FOXP3 on in vitro stimulation.
Increased FOXP3 expression in RAPA-nTregs on in vitro
activation was observed in only one of six patients (data
not shown), indicating that this was unlikely to explain the
rapamycin-associated increased nTreg suppression. Other
explanations include heterogeneity of the Treg subsets in
the sorted CD4
CD25
bright T-cells before and during rapa-
mycin treatment. It has been shown that rapamycin allows
the in vitro generation of inducible human CD4
 Tregs
that are CD25
bright (21,32), and it is possible that rapamy-
cin treatment leads to an increased representation of this
subset in the subsequently puriﬁed T-cells. Alternatively,
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FIG. 5. In vitro suppressive function of FACS-sorted CD4
CD25
bright T-cells. FACS-sorted effector CD4
CD25
 T-cells (10
4 cells) were activated
polyclonally with beads coated with anti-CD3CD28 mAbs in the presence of equal amounts of FACS-sorted CD4
CD25
bright T-cells. Cell
proliferation was assessed in all cultures at day 4 after addition of [
3H]thymidine for the last 18 h of culture except for cells isolated from one
patient (dashed line) that were tested by CFSE dilution assay. Each patient is identiﬁable by a speciﬁc symbol, and each star represents a
different normal donor. The solid line represents average levels of suppression of CD4
CD25
bright T-cells pretreatment in type 1 diabetic patients
(PRE), during treatment in type 1 diabetic patients (RAPA), and in normal donors (ND). A: Syngeneic suppression assays in which effector
CD4
CD25
 T-cells and CD4
CD25
bright nTregs were isolated from the same type 1 diabetic patients and the same normal donor. B: Allogeneic
suppression assays in which effector CD4
CD25
 T-cells were isolated from normal donors (ND) while CD4
CD25
bright nTregs were isolated from
type 1 diabetic patients before (PRE) and during (RAPA) rapamycin treatment. C: Allogeneic suppression assays in which effector CD4
CD25

T-cells were isolated from type 1 diabetic patients before (PRE) and during (RAPA) rapamycin treatment while CD4
CD25
bright nTregs were
isolated from normal donors.
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crucial for nTreg function. Gene expression proﬁling of
T-cells exposed to rapamycin in vivo is currently ongoing
to address this question.
Overall, these data show that rapamycin can reﬁt nTreg
function in vivo in long-term type 1 diabetic patients and
can therefore inﬂuence the consequent islet transplant
outcome. However, the current use of anti-CD25 mAb
therapy (daclizumab) may abrogate this tolerogenic effect
of rapamcyin. We observed that type 1 diabetic patients
undergoing islet transplantation and receiving daclizumab
have a massive depletion of circulating CD4
CD25

FOXP3
 T-cells even months after treatment (P.M. and
M.B., unpublished observation). At present, one of the
major challenges in transplantation is therefore to care-
fully design new combinational therapies so as not to
abrogate the observed positive effects of rapamycin on
nTreg function.
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